Research Pipeline

Infectious Disease

Phase I
Phase II
Phase III
NDA
Market

Cephem antibiotic (injection)

S-649266 (cefiderocol) cUTI Status: Phase III


S-649266 (cefiderocol) Carbapenem resistant gram negative infections Status: Phase III


S-649266 (cefiderocol) HAP/VAP Status: Phase III


Anti-influenza virus infection (oral)

S-033188 (baloxavir marboxil) Influenza virus infection (otherwise healthy patients) Status: NDA Partner: Roche


S-033188 (baloxavir marboxil) Influenza virus infection (high-risk patients) Status: Phase III Partner: Roche


S-033188 (baloxavir marboxil) Influenza virus infection (pediatric) Status: Phase III Partner: Roche


Pain/CNS

Phase I
Phase II
Phase III
NDA
Market

Analgesic agent for pain (oral)

S-120083 Inflammatory pain Status: Phase II Partner: Purdue Pharma


Agent for insomnia (oral)

S-117957 Insomnia Status: Phase I Partner: Purdue Pharma


Metabolic

Phase I
Phase II
Phase III
NDA
Market

Neuropeptide Y Y5 receptor antagonist (oral)

S-237648 Obesity Status: Phase I


Insulin sensitizer (oral)

S-707106 Type 2 diabetes Status: Phase II